IL17A and type 1 diabetes mellitus: Viability (indirect, via activation of immune cells, inflammatory response):• Elevated cargo of inflammatory cytokines in adipose MSC-EVs (healthy donors)• Increased PBMC expression of IFN-γ (T1DM donors)• Increased PBMC expression of IFN-γ, IL-6, IL-10, IL-17, TNF-α, IL-1-β (T1DM and T2DM donors)